Enhanced Anti-Tumor Immune State


Similar to vaccines, traditional immunotherapies target specific epitopes of cancerous cells. While several immunotherapies offer several benefits over other alternatives, immunotherapies are not very effective because of several reasons. Given that microbes/cells have similar epitopes and that tumors mutate, therapy may not work in all cases and tumors may not have the epitope that the immunotherapy was designed to target. Furthermore, therapies are often too specific, and cannot target multiple types of cells.



The current invention describes a novel strategy to reprogram neutrophils or monocytes with selective compound in vitro, into an enhanced anti-tumor immune state that is conducive for the effective treatment of colon cancer and/or solid human tumors. The reprogrammed neutrophils transfer enhanced tumor immune surveillance and reduce tumor burden in vivo. Unlike other immunotherapies, this is an epitope independent immunotherapy process that targets cancer cells.


Microscope image of cells involved in immunotherapy processes.




Patent Information:
For Information, Contact:
Elizabeth Garami
Associate Director
Virginia Tech Intellectual Properties, Inc.
Liwu Li
Yao Zhang
Christina Lee